← All trials
NCT05516784
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Aug 22, 2022
- Completion date
- Aug 22, 2022
- First posted
- Aug 26, 2022
- Last posted
- Sep 1, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Univerisiti Sains MalaysiaLead sponsor
- Penang Medical CollegeOverall official - principal investigator
- University of MalayaOverall official - principal investigator
- Univerisiti Sains MalaysiaReponsible party - principal investigator
- Univerisiti Sains MalaysiaSponsor investigator
- Penang Medical CollegeOfficial
- Univerisiti Sains MalaysiaOfficial
- University of MalayaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.